March 1, 2017
Los Angeles-headquartered Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a manufacturer of a key protein utilized in immunotherapy development pipelines, and Taiwanese biopharmaceutical manufacturer Amaran Biotechnology, Inc., announced that they had entered into an exclusive multi-year supply agreement in connection with clinical development studies of immunotherapies for metastatic breast cancer and other cancers.
The agreement follows a two-year development collaboration between the companies involving the optimization of manufacturing processes for a KLH-conjugated vaccine known as Adagloxad Simolenin, formerly OBI-822, the lead immunotherapy product of Taiwan’s OBI Pharma, Inc (TPEx: 4174). Adagloxad Simolenin is now in late-stage clinical studies. Adagloxad Simolenin is part of a new class of treatments, known as active immunotherapies, which are designed to stimulate a patient’s own immune system to recognize and attack targeted tumor cells.
Read the press release.